A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

February 12, 2021

Study Completion Date

February 4, 2022

Conditions
Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

SHP674

SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m\^2: 2500 IU/m\^2 every 14 days if BSA \<0.6 m\^2: 82.5 IU/kg every 14 days

Trial Locations (8)

Unknown

Kagoshima University Hospital Department of Pediatrics, Kagoshima

Kobe Children's Hospital Department of Hematology/Oncology, Kobe

Nagoya Medical Center Department of Pediatrics, Nagoya

Niigata Cancer Center Hospital, Niigata

Saitama Children's Medical Center Department of Hematology/Oncology, Saitama

Sapporo Hokuyu Hospital Department of Pediatrics and Adolescent Medicine, Sapporo

National Cancer Center Hospital Department of Pediatric Oncology, Tokyo

St. Luke's International Hospital Department of Pediatrics, Tokyo

All Listed Sponsors
collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT04067518 - A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter